Original articlePrognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma
References (19)
- et al.
Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma
Eur J Cancer
(1991) - et al.
Epidermal-growth-factor-receptors and oestrogen receptors in human breast cancer
Lancet
(1985) - et al.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Science
(1987) - et al.
Association of elevated expression of the c-erbB-2 protein with spread of breast cancer
Jpn J Cancer Res
(1989) - et al.
Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients
Jpn J Cancer Res
(1990) - et al.
Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma
J Surg Oncol
(1992) - et al.
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Nature
(1984) - et al.
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
Science
(1985) - et al.
Immunohistochemical study in epidermal growth factor and epidermal growth factor receptor in gastric carcinoma
Cancer
(1989)
Cited by (85)
Lipid rafts, KCa/ClCa/Ca<sup>2 +</sup> channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids?
2015, Biochimica et Biophysica Acta - BiomembranesNSCLC and HER2 between lights and shadows
2014, Journal of Thoracic OncologyThe role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: A meta-analysis of published data
2010, Journal of Thoracic OncologyCitation Excerpt :The dimerization HER2 with an activated EGFR molecule can activate the downstream signaling pathway.3 HER2 is expressed in the breast,72 ovarian,73 osteosarcoma,74 and lung cancer.5,6,19,21,27,28,30,35–37,40,41,43–48,50,51,53–56,58,59,61–66,69–71,75–77 The most extensive study of HER2 was performed in breast cancer, which links to a potentially poor prognosis.4
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
2010, Lung CancerCitation Excerpt :In preclinical studies, both EGFR and HER2 have demonstrated the potential to facilitate transformation to a malignant phenotype independently [106] and synergistically [32]. Indeed, high synchronous coexpression of EGFR and HER2 is associated with an unfavorable prognosis in patients with stage I through IIIA NSCLC [107–109]. Such synchronous overexpression may increase the formation of EGFR/HER2 heterodimers, resulting in a more aggressive phenotype.
A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer
2010, Clinical Lung CancerCitation Excerpt :It may be postulated that synchronous overexpression drives the heterodimerization of EGFR and HER2, which results in increased tumor growth and a decrease in OS and progression-free survival (PFS). Other studies have suggested a relationship between the metastatic potential of NSCLC and EGFR/HER2 coexpression.23 It is noteworthy that increased HER2 gene copy number in EGFR-positive (as measured by immunohistochemistry or fluorescence in situ hybridization) tumors is associated with gefitinib sensitivity and clinical results superior to those seen with tumors that are negative for both receptors.
PKC-δ binds to E-cadherin and mediates EGF-induced cell scattering
2009, Experimental Cell Research